BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38824597)

  • 1. Posttraumatic stress disorder in people who use drugs: syringe services program utilization, treatment need, and preferences for onsite mental health care.
    López-Castro T; Sohler N; Riback L; Bravo G; Ohlendorf E; Ghiroli M; Fox AD
    Harm Reduct J; 2024 Jun; 21(1):108. PubMed ID: 38824597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unmet needs and harm reduction preferences of syringe services program participants: differences by co-use of illicit opioids and methamphetamine.
    Sun R; Sauda TH; Hoopsick RA
    Harm Reduct J; 2024 Jun; 21(1):119. PubMed ID: 38890736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of treatment utilization and unmet treatment need among individuals with posttraumatic stress disorder from a national sample.
    Nobles CJ; Valentine SE; Gerber MW; Shtasel DL; Marques L
    Gen Hosp Psychiatry; 2016; 43():38-45. PubMed ID: 27796256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The lived experiences and treatment needs of women with opioid use disorder and posttraumatic stress symptoms: A mixed methods study.
    Saraiya TC; Helpinstill S; Gray D; Hien DA; Brady KT; Hood CO; Back SE
    J Subst Use Addict Treat; 2024 Jun; 161():209344. PubMed ID: 38492805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral health treatment utilization among individuals with co-occurring opioid use disorder and mental illness: Evidence from a national survey.
    Novak P; Feder KA; Ali MM; Chen J
    J Subst Abuse Treat; 2019 Mar; 98():47-52. PubMed ID: 30665603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation of buprenorphine services in NYC syringe services programs: a qualitative process evaluation.
    Jakubowski A; Rath C; Harocopos A; Wright M; Welch A; Kattan J; Navos Behrends C; Lopez-Castro T; Fox AD
    Harm Reduct J; 2022 Jul; 19(1):75. PubMed ID: 35818071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program.
    Kidorf M; Disney ER; King VL; Neufeld K; Beilenson PL; Brooner RK
    Drug Alcohol Depend; 2004 May; 74(2):115-22. PubMed ID: 15099655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between Medication Assisted Therapy Services Delivery and Mortality in a National Cohort of Veterans with Posttraumatic Stress Disorder and Opioid Use Disorder.
    Riblet NB; Gottlieb DJ; Shiner B; Cornelius SL; Watts BV
    J Dual Diagn; 2020; 16(2):228-238. PubMed ID: 31852392
    [No Abstract]   [Full Text] [Related]  

  • 9. Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs.
    Allen ST; Grieb SM; O'Rourke A; Yoder R; Planchet E; White RH; Sherman SG
    Harm Reduct J; 2019 May; 16(1):33. PubMed ID: 31109339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Barriers to engaging people who use drugs in harm reduction services during the COVID-19 pandemic: A mixed methods study of syringe services program perspectives.
    Austin EJ; Corcorran MA; Briggs ES; Frost MC; Behrends CN; Juarez AM; Frank ND; Healy E; Prohaska SM; LaKosky PA; Kapadia SN; Perlman DC; Schackman BR; Jarlais DCD; Williams EC; Glick SN
    Int J Drug Policy; 2022 Nov; 109():103825. PubMed ID: 35977459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature.
    Jakubowski A; Fowler S; Fox AD
    Addict Sci Clin Pract; 2023 Jun; 18(1):40. PubMed ID: 37301953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment gap and mental health service use among Syrian refugees in Sultanbeyli, Istanbul: a cross-sectional survey.
    Fuhr DC; Acarturk C; McGrath M; Ilkkursun Z; Sondorp E; Sijbrandij M; Ventevogel P; Cuijpers P; McKee M; Roberts B
    Epidemiol Psychiatr Sci; 2019 Nov; 29():e70. PubMed ID: 31727205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interest in Getting Help to Reduce or Stop Substance Use Among Syringe Exchange Clients Who Use Opioids.
    Frost MC; Williams EC; Kingston S; Banta-Green CJ
    J Addict Med; 2018; 12(6):428-434. PubMed ID: 29889118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heightened healthcare utilization & risk of mental disorders among Veterans with comorbid opioid use disorder & posttraumatic stress disorder.
    Mahoney CT; Moshier SJ; Keane TM; Marx BP
    Addict Behav; 2021 Jan; 112():106572. PubMed ID: 32861102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychiatric and Substance Use Comorbidity in Treatment-Seeking Injection Opioid Users Referred From Syringe Exchange.
    Kidorf M; Solazzo S; Yan H; Brooner RK
    J Dual Diagn; 2018; 14(4):193-200. PubMed ID: 30332349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posttraumatic stress disorder and chronic pain are associated with opioid use disorder: Results from a 2012-2013 American nationally representative survey.
    Bilevicius E; Sommer JL; Asmundson GJG; El-Gabalawy R
    Drug Alcohol Depend; 2018 Jul; 188():119-125. PubMed ID: 29775955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between residential treatment length, PTSD, and outpatient healthcare utilization among veterans.
    Banducci AN; Bonn-Miller MO; Timko C; Rosen CS
    Psychol Serv; 2018 Nov; 15(4):529-535. PubMed ID: 29265844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of COVID-19 on New York State's Drug User Health Hubs and syringe service programs: a qualitative study.
    Ude M; Behrends CN; Kelly S; Schackman BR; Clear A; Goldberg R; Gelberg K; Kapadia SN
    Harm Reduct J; 2023 Feb; 20(1):12. PubMed ID: 36732773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among Urban Syringe Service Program Participants.
    Fox AD; Riback L; Perez-Correa A; Ohlendorf E; Ghiroli M; Behrends CN; López-Castro T
    Subst Use Addctn J; 2024 Jan; 45(1):44-53. PubMed ID: 38258851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychiatric comorbidity is associated with drug use and HIV risk in syringe exchange participants.
    Disney E; Kidorf M; Kolodner K; King V; Peirce J; Beilenson P; Brooner RK
    J Nerv Ment Dis; 2006 Aug; 194(8):577-83. PubMed ID: 16909065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.